The role of fMRI in drug development

Owen Carmichael, Adam J. Schwarz, Christopher H. Chatham, David Scott, Jessica A. Turner, Jaymin Upadhyay, Alexandre Coimbra, James A. Goodman, Richard Baumgartner, Brett A. English, John W. Apolzan, Preetham Shankapal, Keely R. Hawkins

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Functional magnetic resonance imaging (fMRI) has been known for over a decade to have the potential to greatly enhance the process of developing novel therapeutic drugs for prevalent health conditions. However, the use of fMRI in drug development continues to be relatively limited because of a variety of technical, biological, and strategic barriers that continue to limit progress. Here, we briefly review the roles that fMRI can have in the drug development process and the requirements it must meet to be useful in this setting. We then provide an update on our current understanding of the strengths and limitations of fMRI as a tool for drug developers and recommend activities to enhance its utility. Brain fMRI has the potential to become a powerful tool for clinical trials but is currently underutilized. Here, we explain why and present a path forward.

Original languageEnglish (US)
JournalDrug Discovery Today
DOIs
StateAccepted/In press - Jan 1 2017
Externally publishedYes

Fingerprint

Magnetic Resonance Imaging
Pharmaceutical Preparations
Clinical Trials
Health
Brain
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Carmichael, O., Schwarz, A. J., Chatham, C. H., Scott, D., Turner, J. A., Upadhyay, J., ... Hawkins, K. R. (Accepted/In press). The role of fMRI in drug development. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2017.11.012

The role of fMRI in drug development. / Carmichael, Owen; Schwarz, Adam J.; Chatham, Christopher H.; Scott, David; Turner, Jessica A.; Upadhyay, Jaymin; Coimbra, Alexandre; Goodman, James A.; Baumgartner, Richard; English, Brett A.; Apolzan, John W.; Shankapal, Preetham; Hawkins, Keely R.

In: Drug Discovery Today, 01.01.2017.

Research output: Contribution to journalArticle

Carmichael, O, Schwarz, AJ, Chatham, CH, Scott, D, Turner, JA, Upadhyay, J, Coimbra, A, Goodman, JA, Baumgartner, R, English, BA, Apolzan, JW, Shankapal, P & Hawkins, KR 2017, 'The role of fMRI in drug development', Drug Discovery Today. https://doi.org/10.1016/j.drudis.2017.11.012
Carmichael O, Schwarz AJ, Chatham CH, Scott D, Turner JA, Upadhyay J et al. The role of fMRI in drug development. Drug Discovery Today. 2017 Jan 1. https://doi.org/10.1016/j.drudis.2017.11.012
Carmichael, Owen ; Schwarz, Adam J. ; Chatham, Christopher H. ; Scott, David ; Turner, Jessica A. ; Upadhyay, Jaymin ; Coimbra, Alexandre ; Goodman, James A. ; Baumgartner, Richard ; English, Brett A. ; Apolzan, John W. ; Shankapal, Preetham ; Hawkins, Keely R. / The role of fMRI in drug development. In: Drug Discovery Today. 2017.
@article{6b976450501d49f18298b0fe64dc65c2,
title = "The role of fMRI in drug development",
abstract = "Functional magnetic resonance imaging (fMRI) has been known for over a decade to have the potential to greatly enhance the process of developing novel therapeutic drugs for prevalent health conditions. However, the use of fMRI in drug development continues to be relatively limited because of a variety of technical, biological, and strategic barriers that continue to limit progress. Here, we briefly review the roles that fMRI can have in the drug development process and the requirements it must meet to be useful in this setting. We then provide an update on our current understanding of the strengths and limitations of fMRI as a tool for drug developers and recommend activities to enhance its utility. Brain fMRI has the potential to become a powerful tool for clinical trials but is currently underutilized. Here, we explain why and present a path forward.",
author = "Owen Carmichael and Schwarz, {Adam J.} and Chatham, {Christopher H.} and David Scott and Turner, {Jessica A.} and Jaymin Upadhyay and Alexandre Coimbra and Goodman, {James A.} and Richard Baumgartner and English, {Brett A.} and Apolzan, {John W.} and Preetham Shankapal and Hawkins, {Keely R.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.drudis.2017.11.012",
language = "English (US)",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The role of fMRI in drug development

AU - Carmichael, Owen

AU - Schwarz, Adam J.

AU - Chatham, Christopher H.

AU - Scott, David

AU - Turner, Jessica A.

AU - Upadhyay, Jaymin

AU - Coimbra, Alexandre

AU - Goodman, James A.

AU - Baumgartner, Richard

AU - English, Brett A.

AU - Apolzan, John W.

AU - Shankapal, Preetham

AU - Hawkins, Keely R.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Functional magnetic resonance imaging (fMRI) has been known for over a decade to have the potential to greatly enhance the process of developing novel therapeutic drugs for prevalent health conditions. However, the use of fMRI in drug development continues to be relatively limited because of a variety of technical, biological, and strategic barriers that continue to limit progress. Here, we briefly review the roles that fMRI can have in the drug development process and the requirements it must meet to be useful in this setting. We then provide an update on our current understanding of the strengths and limitations of fMRI as a tool for drug developers and recommend activities to enhance its utility. Brain fMRI has the potential to become a powerful tool for clinical trials but is currently underutilized. Here, we explain why and present a path forward.

AB - Functional magnetic resonance imaging (fMRI) has been known for over a decade to have the potential to greatly enhance the process of developing novel therapeutic drugs for prevalent health conditions. However, the use of fMRI in drug development continues to be relatively limited because of a variety of technical, biological, and strategic barriers that continue to limit progress. Here, we briefly review the roles that fMRI can have in the drug development process and the requirements it must meet to be useful in this setting. We then provide an update on our current understanding of the strengths and limitations of fMRI as a tool for drug developers and recommend activities to enhance its utility. Brain fMRI has the potential to become a powerful tool for clinical trials but is currently underutilized. Here, we explain why and present a path forward.

UR - http://www.scopus.com/inward/record.url?scp=85034079434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034079434&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2017.11.012

DO - 10.1016/j.drudis.2017.11.012

M3 - Article

AN - SCOPUS:85034079434

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

ER -